SynCo Bio Partners and Prosensa will collaborate in the formulation and fill of Prosensa’s RNA-based therapeutics for Duchenne muscular dystrophy (DMD).
"SynCo is pleased to be working with Prosensa on this important clinical program for the life-saving treatment of DMD,” Pierre Warffemius, CEO of SynCo commented. “We aim to establish a long-term relationship with Prosensa to support their expanding portfolio of nucleic acid based therapeutics against neuromuscular disorders by providing high quality aseptic formulation and filling services."